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after palliative radiotherapy for painful bone
metastases: a multicenter double-blind
placebo-controlled randomized trial
Paulien G Westhoff1*, Alexander de Graeff2, Jenske I Geerling3, Anna KL Reyners3 and Yvette M van der Linden4Abstract
Background: Radiotherapy has a good effect in palliation of painful bone metastases, with a pain response rate of
more than 60%. However, shortly after treatment, in approximately 40% of patients a temporary pain flare occurs,
which is defined as a two-point increase of the worst pain score on an 11-point rating scale compared to baseline,
without a decrease in analgesic intake, or a 25% increase in analgesic intake without a decrease in worst pain score,
compared to baseline. A pain flare has a negative impact on daily functioning and mood of patients. It is thought
to be caused by periostial edema after radiotherapy. Dexamethasone might diminish this edema and thereby
reduce the incidence of pain flare. Two non-randomized studies suggest that dexamethasone reduces the
incidence of a pain flare by 50%. The aim of this trial is to study the effectiveness of dexamethasone to prevent a
pain flare after palliative radiotherapy for painful bone metastases and to determine the optimal dose schedule.
Methods and design: This study is a three-armed, double-blind, placebo-controlled multicenter trial. We aim to
include 411 patients with uncomplicated painful bone metastases from any type of primary solid tumor who
receive short schedule radiotherapy (all conventional treatment schedules from one to six fractions). Arm 1 consists
of daily placebo for four days, arm 2 starts with 8 mg dexamethasone before the (first) radiotherapy and three days
placebo thereafter. Arm 3 consists of four days 8 mg dexamethasone. The primary endpoint is the occurrence of a
pain flare. Secondary endpoints are pain, quality of life and side-effects of dexamethasone versus placebo. Patients
complete a questionnaire (Brief Pain Inventory with two added questions about side-effects of medication, the
EORTC QLQ-C15-PAL and QLQ-BM22 for quality of life) at baseline, daily for two weeks and lastly at four weeks.
Discussion: This study will show whether dexamethasone is effective in preventing a pain flare after palliative
radiotherapy for painful bone metastases and, if so, to determine the optimal dose.
Trial registration: This study is registered at ClinicalTrials.gov: NCT01669499
Keywords: Pain flare, Palliative radiotherapy, Dexamethasone, Bone metastasesBackground
Radiotherapy, with a single fraction of 8 Gray as the gold
standard, has a good effect in palliation of painful bone
metastases, with a pain response rate of more than 60%.
[1] However, a possible side-effect is a transient progres-
sion of pain, the so-called pain flare. This pain flare is* Correspondence: p.g.westhoff@umcutrecht.nl
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unless otherwise stated.defined as a two-point increase of the worst pain score
on an 11-point rating scale, compared to baseline, with-
out a decrease in analgesic intake, or a 25% increase in
analgesic intake without a decrease in worst pain score.
A pain flare is distinguished from progression of pain by
requiring the worst pain score and analgesic intake to
return to baseline levels after the flare [2].
Two prospective observational studies show that ap-
proximately 40% of patients experience a pain flare [3,4].
Hird studied 111 patients with uncomplicated painfulal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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of 40%, with no difference between single or multiple
fractions. The median duration of a pain flare was
1.5 days, while 25% of patients had more than one pain
flare. Most of the pain flares occurred during the first
five days after treatment. A pain flare occurred in 52%
of patients with breast cancer and in 25% of patients
with prostate cancer [3]. Loblaw studied 44 patients
and found, with an adjusted, underestimating defin-
ition of a pain flare, an incidence of 41%, with a signifi-
cant difference between single and multiple fractions
(57% and 24% respectively) [4].
A survey among patients who experienced a pain flare
showed that having a pain flare had a negative effect on
daily functioning of patients and on their mood [5]. Most
patients tried to manage their pain flare by increasing
their pain medication, at the cost of possible side-effects.
The majority of patients who experienced a pain flare
stressed the need for prevention of this pain flare in-
stead of managing it with breakthrough medication.
The pain flare is thought to arise through edema of
the periostium of the irradiated bone. Dexamethasone,
an anti-inflammatory drug decreasing edema, may be an
effective drug. Two small studies were performed to
study the effect of dexamethasone on the incidence of pain
flare [6,7]. In the study by Chow a single dose of 8 mg dexa-
methasone was prescribed one hour before the single frac-
tion radiotherapy. This study included 33 patients and
showed an overall pain flare incidence of 24%. Most of
the observed pain flares commenced after the half-life
of dexamethasone [7], suggesting that a longer treatment
time might be useful. Dexamethasone was well tolerated.
A subsequent study, with 41 evaluable patients, used 8 mg
dexamethasone before single fraction radiotherapy and
then daily for three consecutive days. It showed an overall
incidence of pain flare of 22%, with a median duration of
one day [6].
Both studies concluded that randomized trials are ne-
cessary to study the effectiveness of dexamethasone for
prevention of a pain flare. No randomized trials have been
published so far. Therefore, the aim of this trial is to study
the effectiveness of dexamethasone to prevent a pain flare
after palliative radiotherapy for painful bone metastases
and to determine the optimal dose schedule.
Methods/Design
Design
This three-armed, prospective, randomized, placebo-
controlled multicenter study is being led by the University
Medical Center Utrecht. The study is supported by grants
from the Dutch Cancer Society and ZonMw. It is registered
at ClinicalTrials.gov: NCT01669499. The study compares
two different dose schedules of dexamethasone with a
placebo (Figure 1). The aim is to study the effectivenessof dexamethasone to prevent the occurrence of a pain
flare after radiotherapy for painful bone metastases and to
define the optimal schedule of dosing. Secondary endpoints
are pain scores, quality of life and side-effects of placebo
and dexamethasone. In addition, the predictive value of
a pain flare for response to the palliative radiotherapy
will be studied.
Patients
The study includes patients with uncomplicated painful
bone metastases from a solid tumor, who are referred
for a short course of palliative radiotherapy. Short course
radiotherapy encompasses all conventional treatment
schedules from one to six fractions of radiotherapy. The
full inclusion and exclusion criteria are listed in Table 1.
Patients are randomized between the three treatment
arms (Figure 1), after stratification for center and treatment
schedule: single or multiple fractions. Randomization is
performed by telephone at the Comprehensive Cancer
Center The Netherlands. Double-blind randomization is
guaranteed by only communicating the number of the
medication box to patients and physicians.
Participating centers
In total, 12 out of the 21 radiotherapy departments in
the Netherlands participate in this nationwide study.
Patients are asked for participation at these departments.
Participating centers are:
University Medical Center Utrecht, Utrecht
Leiden University Medical Center, Leiden
MAASTRO Clinic, Maastricht
Medical Center Haaglanden, den Haag
The Netherlands Cancer Institute-Antoni van
Leeuwenhoek Hospital, Amsterdam
Medical Spectrum Twente, Enschede
Erasmus Medical Center, Rotterdam
ARTI Institute for Radiation Oncology Arnhem, Arnhem
Institute Verbeeten, Tilburg
Catharina Hospital, Eindhoven
Zeeuws Radiotherapeutic Institute, Vlissingen
Reinier de Graaf Gasthuis, Delft
Ethics, informed consent and safety
The protocol has been approved by the medical ethics
committee of the University Medical Center Utrecht. In
the participating centers, local medical ethics commit-
tees have approved the protocol. The study is conducted
in accordance with the Declaration of Helsinki. Written
informed consent, signed and dated, is obtained before
randomization. Serious adverse events (SAE) or suspected
unexpected serious adverse reactions (SUSAR), as defined
in the study protocol, are reported to the central medical
Figure 1 Treatment arms.
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research involving human subjects.
Endpoints and analysis
Participating patients fill out a questionnaire at baseline
(the start of treatment, defined as day 1), then daily until
day 15 and a final questionnaire at day 29. The question-
naire contains the Brief Pain Inventory [8], which notes
the level of pain on a 11 point pain scale ranging from 0
(no pain) to 10 (worst imaginable pain). Two questionsTable 1 Full inclusion and exclusion criteria
Inclusion Patients of 18 years or older
Uncomplicated painful bone metastases
Primary malignancy is a solid tumor
Pain intensity on a numeric rating scale of 2-8
No immediately expected change in the analgesic regimen.
Indication for single or short course radiotherapy
Able to fill out Dutch questionnaires
Able to follow instructions
Informed consent provided
Exclusion Patients with haematological malignancy
Multiple sites to be irradiated
Patients who have been treated before with palliative
radiotherapy for painful bone metastases to the same
bony localisation
Current use of steroids (dexamethasone, prednisolone or other),
use up to less than a week before randomization or
expected use within 2 weeks after start of radiotherapy
(e.g., as part of anti-emetic regimen for chemotherapy)
Contraindications for the use of dexamethasone
(to be judged by the radiation-oncologist)
Long-term schedule radiotherapy (>6 fractions)
Life expectancy shorter than 8 weeks
Karnofsky performance score of 40 or lessare added about side-effects of the study medication
(‘Do you have appetite?’ and ‘Do you feel restless?’). To
assess quality of life, the EORTC QLQ-C15-PAL [9] and
the EORTC QLQ-BM22 [10] are added (both at baseline,
day 8, 15 and 29). Reminder telephone calls are performed
twice during the study. The researchers contact partici-
pants who do not return their questionnaires. The occur-
rence of a pain flare, the primary endpoint of the study, is
determined using the daily noted pain scores and pain
medication. Pain response and side-effects of placebo and
dexamethasone are assessed by the daily questionnaires.
Analysis will be by intention-to-treat. Patients who have
received at least one fraction of radiotherapy, irrespective of
study medication intake, and have returned questionnaires
are evaluable. Descriptive analyses of baseline characteris-
tics will be performed. Comparison of occurrence of pain
flare between the three arms will be assessed using the
Chi-Square test. Comparison of pain intensity, quality of life
items and side effects at baseline and over time between
the three arms will be done using multilevel analysis. Since
the risks of the study using well-known medication are con-
sidered minimal, an interim analysis will not be performed.
Power calculation
Assuming a reduction of 50% (from 40 to 20%) of the
occurrence of a pain flare by administering a single dose of
8 mg dexamethasone, a total of 411 patients are necessary
(137 per arm) to reach a power of 90% given a significance
level of 5% (2-sided), and assuming a drop-out of 20% dur-
ing follow-up. In the Netherlands, around 3000 patients are
eligible for this study yearly. With 12 out of 21 institutions
participating and an estimated participation rate of 20%,
the total study time needed is about 2 years.
Discussion
Up to 40% of patients experience a pain flare after palliative
radiotherapy for painful bone metastases [3,4]. A pain flare
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[5]. Therefore, it is clinically important to prevent the
occurrence of a pain flare. Earlier publications suggest
an effect of dexamethasone on the incidence of pain
flare [6,7]. Although side-effects of a short course and
relative low dosage of dexamethasone are considered
minimal, the beneficial effect in this patient population
should be proven before integrating dexamethasone
medication into daily clinical radiotherapy practice. A
prolonged schedule of dexamethasone might be better
in preventing a pain flare. Therefore, in the present
trial, we study different schedules, to be able to determine
which one is the optimum schedule.
A recent publication from Chiang et al. (published
after the initiation of our study) in patients treated
with stereotactic radiotherapy for painful bone metasta-
ses showed an incidence of pain flare of 68%. However,
this might be an overestimation. Firstly, they did not
mention to require pain score and analgesic intake to
return to baseline, to distinguish it from progression.
Secondly, initiation of corticosteroids during or after
treatment was considered to be indicative of a pain flare
[11]. Nevertheless, these results give rise to the assump-
tion that this group of patients might also benefit from
our treatment results. However, the results of our study
are not directly applicable to patients who are treated
with stereotactic radiotherapy for painful bone metastases,
since they represent a highly selected group of patients
who receive much higher total doses of radiotherapy
(e.g. 1 × 20 Gy, or 3 × 8 Gy).
Using consensus definitions of endpoints in literature is
important, to be able to compare studies [12]. Most pub-
lished studies concerning pain flare after palliative radio-
therapy use the definition by Chow [2], incorporating pain
scores, analgesics intake and returning to baseline to distin-
guish it from progression. Loblaw et al. [4] used a different
definition for pain flare. They tried to convert it into the
definition by Chow [2], but since they used a different pain
scale, this was not completely possible, which made it diffi-
cult to interpret and compare these results with other pub-
lished studies. We chose to also use the definition by Chow
[2], to enable comparison with other studies.
In conclusion, if this study proves the effectiveness of
dexamethasone in the prevention of a pain flare after
palliative radiotherapy for painful bone metastases, this
should lead to a change in supportive care. Since we
use a commonly accepted definition of pain flare, com-
parison between our results and future results from
other trials may be possible. It may also lead to studies
of the benefit of dexamethasone in preventing a pain
flare after stereotactic radiotherapy.
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